Newron Pharmaceuticals S.p.A.
Biopharmaceutical company developing therapies for nervous system disorders and pain.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Manufacturing
Description
Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-12 07:00 |
Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide…
|
English | 17.2 KB | ||
| 2025-08-12 02:00 |
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with…
|
English | 15.8 KB | ||
| 2025-08-12 02:00 |
EQS-News: Newron beginnt Rekrutierung für zulassungsrelevantes Phase-III-Entwic…
|
German | 18.5 KB | ||
| 2025-08-11 07:00 |
Newron notes the publication of new preclinical research suggesting evenamide a…
|
English | 19.4 KB | ||
| 2025-08-11 02:00 |
EQS-News: Newron notes the publication of new preclinical research suggesting e…
|
English | 17.8 KB | ||
| 2025-08-11 02:00 |
EQS-News: Newron verweist auf die Veröffentlichung neuer präklinischer Forschun…
|
German | 20.9 KB | ||
| 2025-05-12 07:00 |
Newron gibt Genehmigung fur zulassungsrelevantes Phase-III-Entwicklungsprogram…
|
German | 12.6 KB | ||
| 2025-05-12 02:00 |
EQS-Adhoc: Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwickl…
|
German | 11.3 KB | ||
| 2025-05-12 02:00 |
EQS-News: Newron announces approval for pivotal Phase III ENIGMA-TRS program w…
|
English | 19.4 KB | ||
| 2025-05-12 02:00 |
EQS-News: Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwicklu…
|
German | 22.8 KB | ||
| 2025-04-24 16:22 |
Newron Pharmaceuticals S.p.A.: Tuula Martin, buy
|
English | 6.3 KB | ||
| 2025-04-23 11:30 |
Generalversammlung 2025 von Newron Pharmaceuticals: Chris Martin zum neuen Verw…
|
German | 7.5 KB | ||
| 2025-04-07 17:17 |
Newron Pharmaceuticals S.p.A.: Stefan Weber, buy
|
English | 5.9 KB | ||
| 2025-04-01 07:00 |
Newron gibt Geschaftsergebnisse 2024 und Ausblick 2025 bekannt
|
German | 12.5 KB | ||
| 2025-03-24 17:45 |
Newron schlagt renommierten Biopharma-Firmengrunder und -Unternehmer Dr. Chris …
|
German | 8.9 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Newron Pharmaceuticals S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
